Theranostics-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2022-03-27 121fe4bem50(暂无昵称)

审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56
偏重的研究方向：纳米材料;治疗;炎症
经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!

310 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2023-06-11 ms1000001915586681 来自湖北省

北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。

69 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2023-08-07 ms1000001071114290 来自重庆

偏重的研究方向：肿瘤
经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛

35 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2020-05-13 ms5075507494691300

审稿速度:3.0
经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多

91 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2023-08-02 周大-Jagger 来自天津

请问这个杂志需要全部作者邮件确认才能投稿吗？

45 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2023-04-07 ms3000000361924578 来自北京

想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。

42 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2018-12-28 124bde92m63暂无昵称

请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等

132 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2019-12-28 Avafang

请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表:
请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等

182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等

102 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2020-01-28 枫杨阿婷

您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表::
请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表:
请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？

yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？

90 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1206377, encodeId=65a612063e7bb, content=审稿速度:1.0 | 投稿命中率:25.0 | 影响因子:11.56 偏重的研究方向：纳米材料;治疗;炎症 经验分享：投稿20天大修，5个审稿意见，疯狂补了2个月实验，修回后2天通知改格式并接受。审稿人非常专业且严格，给出的意见极具建设性，主编认真负责，处理飞速，严格把控文章质量。以后还会选择Theranostics!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=310, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05152298035, createdName=121fe4bem50(暂无昵称), createdTime=Sun Mar 27 15:25:32 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142158, encodeId=334521421586e, content=北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。《Theranostics》最新CiteScore高达20.9，再次证明了其在国际学术界的重要地位和影响力。《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:36:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151564, encodeId=f9c22151564cb, content=偏重的研究方向：肿瘤 经验分享：请问修回的时候需要提供补充材料，但是确没有地方可以上传，是将补充材料放到正文里一起传嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=451d8358177, createdName=ms1000001071114290, createdTime=Mon Aug 07 07:04:43 CST 2023, time=2023-08-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=860516, encodeId=308a860516d9, content=审稿速度:3.0 经验分享：啥治疗杂志啊，上面一堆灌水的信号通路的文章，随便搞个小分子药物捣鼓捣鼓相关的信号通路，感觉都是从其它一线杂志被拒了以后来这里的，关系户巨多 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50165414105, createdName=ms5075507494691300, createdTime=Wed May 13 17:44:33 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150925, encodeId=e6a821509256d, content=请问这个杂志需要全部作者邮件确认才能投稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Wed Aug 02 15:28:37 CST 2023, time=2023-08-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2124285, encodeId=44572124285c2, content=想请教各位投稿过的前辈，如何知道自己的稿件外审了，已经under review三天没消息了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Fri Apr 07 13:53:13 CST 2023, time=2023-04-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582286, encodeId=a3c858228691, content=请问后来怎么样了？我这边通讯作者邮箱一直不能登录，所以用了一作邮箱投的。。182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=182****1163暂无昵称 2018-12-28 00:00:00 发表: 请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/07/dea5761ee705f6a08a6442c3f43bb504.jpg, createdBy=cd671656886, createdName=Avafang, createdTime=Sat Dec 28 00:00:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583932, encodeId=84eb58393211, content=您好，您的文章状态是怎样的呢？我投稿五天了，还是received，同时，我没用通讯作者的邮箱，而是一作的，编辑来信语气不太友好。yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？yyyanz 2019-05-25 00:00:00 发表: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, beContent=yyyanz 2019-05-25 发表:: 请问您的稿子一审多久？我投过去20天了，一直处于active-under review状态，不知道是不是送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34d21967398, createdName=枫杨阿婷, createdTime=Tue Jan 28 00:00:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142159, encodeId=9bc7214215929, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cfa5475223, createdName=ms1000001915586681, createdTime=Sun Jun 11 08:38:37 CST 2023, time=2023-06-11, status=1, ipAttribution=湖北省)]

2023-06-11 ms1000001915586681 来自湖北省

#期刊论坛#《Theranostics》在医学（Medicine）学科收录的309种期刊中排名第5；在药理学，毒理学和药剂学（Pharmacology, Toxicology and Pharmaceutics）学科收录的32种期刊中排名第1，其学术水平和影响力得到了广泛的认可。北京时间2023年6月7日，2022年度爱思唯尔CiteScore™（引用分)指标正式发布，该指标对收录于Scopus数据库的28,100多种同行评议期刊、系列图书、会议论文和行业刊物的影响力做出最新评估。

179 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务